Drug intelligence / Profile preview

Farnesol

Development stage
Preclinical
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration
Topical, Oral, Inhalation
01

Overview

Farnesol is a natural 15-carbon acyclic sesquiterpene alcohol found in many aromatic plants and essential oils such as citronella, neroli, cyclamen, lemongrass, tuberose, rose, musk, balsam, and tolu[4][8]. It is hydrophobic and used primarily in perfumery to enhance sweet floral scents by acting as a co-solvent that regulates the volatility of odorants[4][8]. Farnesol also serves as a natural pesticide for mites and acts as a pheromone for several insects[5][8]. In nature and biology (notably in Candida albicans), it functions as a quorum-sensing molecule that inhibits filamentation[4]. Mechanistically in mammals and other organisms it has been shown to act on nuclear receptors and modulate voltage-gated calcium channels—specifically inhibiting N-type Ca2+ channels (and possibly L-type Ca2+ channels)—which may impact neurotransmitter release or smooth muscle function[6]. Farnesol can also modulate drug efflux mediated by ABC transporter proteins in fungi like C. albicans; this effect can synergize with antifungal drugs by promoting reactive oxygen species accumulation leading to apoptosis[3]. It has been investigated for potential anticancer properties but is not an approved pharmaceutical drug for any indication at this time[8].

Other names
3,7,11-trimethyl-2,6,10-dodecatriene-1-ol
02

Targets

NR (Nuclear receptors (steroid))ABC family (ATP-binding cassette transporter family)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on Farnesol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Farnesol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call